Anglo-Swedish pharmaceuticals giant AstraZeneca on Tuesday agreed to buy US biopharma firm Fusion for up to $2.4 billion, in the group’s latest expansion into cancer treatments.
Wed. Jun 26th, 2024
Anglo-Swedish pharmaceuticals giant AstraZeneca on Tuesday agreed to buy US biopharma firm Fusion for up to $2.4 billion, in the group’s latest expansion into cancer treatments.